StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) shareholders

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)

Close on Nov 17, 2026Market cap $855.51MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
84.1%
71M of 84M shares
Institutional holders
174
41 new, 30 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $384.13K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp V LLC (12.20%)
9,785,42312.20%13D (active) amendmentMay 12, 2025
Orbimed Capital Gp V LLC
Joint filing with Orbimed Advisors LLC (10.30%)
8,609,09110.30%13D (active) amendmentJan 23, 2026
Sirenia Capital Management LP
Joint filing with Alex Silverstein (7.50%)
6,831,8287.50%13G (passive)Mar 31, 2026
BlackRock, Inc.6,325,1577.50%13G (passive) amendmentJun 30, 2026
Richard A. Miller6,085,9227.80%13G (passive) amendmentDec 31, 2025
Samlyn, LP
Joint filing with Samlyn Capital, LLC (6.00%), Robert Pohly (6.00%)
4,065,9356.00%13G (passive) amendmentMar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CRVSValueChange% of portfolio
Orbimed Advisors LLC7,165,0068.52%$107.05M–1.98%
BlackRock, Inc.7,138,8118.49%$106.65M+978,3890.00%
State Street Corp4,474,0915.32%$66.84M+908,0990.00%
Price T Rowe Associates Inc /Md/3,789,1264.50%$56.61M+871,8260.01%
Vanguard Capital Management LLC3,292,7103.91%$49.19M+58,1720.00%
Adams Street Partners LLC3,275,6163.89%$48.94M–11.06%
Vivo Capital, LLC2,805,8163.34%$41.92M–3.83%
Wellington Management Group Llp2,731,6323.25%$40.81M+413,1150.01%
Perceptive Advisors LLC2,667,4413.17%$39.85M+375,0000.60%
Deep Track Capital, LP2,491,9392.96%$37.23M+4000.54%
Braidwell LP2,126,2982.53%$31.77M+373,5001.18%
Geode Capital Management, LLC1,853,6592.20%$27.70M+140,9180.00%
Foresite Capital Management VI LLC1,831,2332.18%$27.36M–4.26%
Goldman Sachs Group Inc1,576,3521.87%$23.55M+35,5430.00%
Hood River Capital Management LLC1,571,8051.87%$23.48M+236,6960.17%
Morgan Stanley1,344,7361.60%$20.09M−1,154,0890.00%
Boxer Capital Management, LLC1,100,0001.31%$16.43M–1.24%
Catalio Capital Management, LP1,080,8881.28%$16.15M+188,9553.03%
Millennium Management LLC1,047,9851.25%$15.66M+181,6230.01%
Vanguard Portfolio Management LLC814,7500.97%$12.17M+144,8550.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202617471M84.1%41 / 7040 / 3010M9M
Q1 202616470M83.3%68 / 5530 / 2635M8M
Q4 202512447M55.6%30 / 4228 / 713M8M
Q3 202510242M49.6%23 / 3417 / 133M3M
Q2 20259242M49.8%33 / 3210 / 2914M9M
Q1 20258836M43.1%16 / 2623 / 134M5M
Q4 20248538M44.9%32 / 3012 / 812M4M
Q3 20246230M35.8%19 / 179 / 36M3M
Q2 20244728M32.8%7 / 1111 / 710M1M
Q1 20244719M22.0%7 / 1113 / 81M2M
Q4 20234819M23.1%3 / 1311 / 71M1M
Q3 20235219M22.8%10 / 1512 / 101M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

167 funds held CRVS in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CRVSValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2,931,6443.49%$43.80M0.41%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,374,1062.82%$35.47M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,748,0432.08%$26.12M0.03%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.963,9581.15%$14.40M0.10%Jun 30, 2026
Vanguard Extended Market Index Fund844,7221.00%$12.62M0.01%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund801,9000.95%$11.98M0.12%Jun 30, 2026
Fidelity Small Cap Index Fund740,5140.88%$9.82M0.03%Jul 31, 2026
Hood River Small-Cap Growth Fund707,1930.84%$10.57M0.16%Jun 30, 2026
iShares Russell 2000 Growth ETF625,7700.74%$9.35M0.06%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.616,3910.73%$9.21M0.08%Jun 30, 2026
iShares Biotechnology ETF445,6730.53%$6.66M0.07%Jun 30, 2026
Fidelity Extended Market Index Fund380,9130.45%$4.73M0.01%May 31, 2026
Vanguard Russell 2000 Index Fund330,8630.39%$4.11M0.02%May 31, 2026
Vanguard Explorer Fund290,6750.35%$3.85M0.02%Jul 31, 2026
iShares Micro-Cap ETF223,5990.27%$3.34M0.22%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Richard A. Miller MdPresident and CEO, Director2,331,7422.77%May 20, 2026
Jeffrey ArcaraChief Business Officer4,5000.01%Nov 13, 2026
Leiv LeaChief Financial Officer282,4440.34%Dec 8, 2025
William Benton JonesSee Remarks173,1300.21%Dec 8, 2025
den Broek Richard vanDirector160,0000.19%Jun 15, 2026
David Scott MooreDirector21,7000.03%Jun 15, 2026
Linda GraisDirector10,0000.01%Jun 15, 2026
Peter A. ThompsonDirector, 10% owner8,729,09110.38%Jun 15, 2026
Ian T. ClarkDirector––Jun 15, 2026
Andrew C. ChanDirector––Apr 27, 2026
Capital GP V. LLC OrbiMedDirector, 10% owner6,943,6548.25%Jul 1, 2025
Advisors Llc OrbimedDirector, 10% owner8,341,3389.92%Jul 1, 2025
Scott W. MorrisonDirector––Jun 16, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jeffrey Arcara
Chief Business Officer
Nov 13, 2026Buy+500$10.71$5.35K4,500
Jeffrey Arcara
Chief Business Officer
Nov 13, 2026Buy+503$10.37$5.22K4,000
Jeffrey Arcara
Chief Business Officer
Nov 12, 2026Buy+497$11.12$5.52K3,497
Jeffrey Arcara
Chief Business Officer
Nov 11, 2026Buy+3,000$11.46$34.38K3,000
David Scott Moore
Director
Jun 11, 2026Buy+21,700$11.53$250.20K21,700
Richard A. Miller Md
President and CEO, Director
May 18, 2026Buy+1,932$12.01$23.20K1,195,035
Richard A. Miller Md
President and CEO, Director
May 18, 2026Buy+5,000$12.05$60.25K1,193,103
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$2.74$41.10K120,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$1.64$24.60K195,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$2.49$37.35K180,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$0.97$14.55K165,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$0.99$14.85K150,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$2.60$39.00K135,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$2.12$31.80K210,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$3.27$49.05K105,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$2.00$30.00K90,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$3.61$54.15K75,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$12.50$187.50K60,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+15,000$9.70$145.50K45,000
Peter A. Thompson
Director, 10% owner
Jan 28, 2026Option exercise+30,000$15.00$450.00K30,000
Advisors Llc Orbimed
Director, 10% owner
Jun 27, 2025Option exercise+1,397,684$3.50$4.89M8,341,338
Advisors Llc Orbimed
Director, 10% owner
Jun 27, 2025Sale−1,176,332$4.16$4.89M7,165,006
Peter A. Thompson
Director, 10% owner
Jun 27, 2025Sale−1,176,332$4.16$4.89M7,165,006
Peter A. Thompson
Director, 10% owner
Jun 27, 2025Option exercise+1,397,684$3.50$4.89M8,341,338
William Benton Jones
See Remarks
Jun 4, 2025Option exercise+19,357$3.50$67.75K173,130
Richard A. Miller Md
President and CEO, Director
May 7, 2025Option exercise+559,073$3.50$1.96M1,136,707
Richard A. Miller Md
President and CEO, Director
May 10, 2024Gift−302,016––1,188,103
William Benton Jones
See Remarks
May 6, 2024Buy+20,000$1.73$34.60K153,773
Richard A. Miller Md
President and CEO, Director
May 6, 2024Buy+577,634$1.73$999.31K577,634
Linda Grais
Director
May 15, 2023Buy+10,000$2.45$24.50K10,000
William Benton Jones
See Remarks
Dec 20, 2022Buy+20,000$0.79$15.80K133,773
Richard A. Miller Md
President and CEO, Director
Dec 14, 2022Buy+10,000$0.78$7.80K1,490,119
Leiv Lea
Chief Financial Officer
Dec 14, 2022Buy+4,000$0.84$3.36K133,238
Richard A. Miller Md
President and CEO, Director
Dec 13, 2022Buy+50,000$0.74$37.00K1,480,119
Leiv Lea
Chief Financial Officer
Dec 13, 2022Buy+30,000$0.74$22.20K129,238
Richard A. Miller Md
President and CEO, Director
Sep 28, 2022Buy+25,000$0.76$19.00K1,394,405
Richard A. Miller Md
President and CEO, Director
Sep 20, 2022Buy+12,300$0.81$9.96K1,361,705
Richard A. Miller Md
President and CEO, Director
Sep 20, 2022Buy+5,000$0.82$4.10K1,369,405
Richard A. Miller Md
President and CEO, Director
Sep 20, 2022Buy+2,700$0.82$2.21K1,364,405
Richard A. Miller Md
President and CEO, Director
Jun 27, 2022Buy+5,000$1.00$5.00K1,349,405
Richard A. Miller Md
President and CEO, Director
Jun 24, 2022Buy+5,000$1.03$5.15K1,344,405
Richard A. Miller Md
President and CEO, Director
Jun 6, 2022Buy+890$1.01$8991,339,405
Richard A. Miller Md
President and CEO, Director
Jun 2, 2022Buy+170$0.97$1651,338,515
Richard A. Miller Md
President and CEO, Director
Jun 2, 2022Buy+4,830$0.98$4.73K1,338,345
Richard A. Miller Md
President and CEO, Director
Mar 31, 2022Buy+15,000$1.64$24.60K1,333,515
Richard A. Miller Md
President and CEO, Director
Mar 17, 2022Buy+5,000$1.59$7.95K1,318,515
Leiv Lea
Chief Financial Officer
Mar 17, 2022Buy+13,878$1.65$22.90K99,238
Leiv Lea
Chief Financial Officer
Mar 16, 2022Buy+35,160$1.54$54.15K85,360
Richard A. Miller Md
President and CEO, Director
Mar 15, 2022Buy+25,000$1.47$36.75K1,313,515
EcoR1 Capital, LLC
10% owner
Oct 1, 2021Sale−2,000,000$4.96$9.92M81,077
EcoR1 Capital, LLC
10% owner
Sep 30, 2021Sale−3,000,000$5.04$15.12M2,081,077
Peter A. Thompson
Director, 10% owner
Sep 20, 2021Sale−1,109,644$6.09$6.76M6,943,654
Capital GP V. LLC OrbiMed
Director, 10% owner
Sep 20, 2021Sale−1,109,644$6.09$6.76M6,943,654
Richard A. Miller Md
President and CEO, Director
Aug 20, 2021Buy+10,000$1.93$19.30K1,288,515
Richard A. Miller Md
President and CEO, Director
May 4, 2021Buy+35,714$2.80$100.00K35,714
Peter A. Thompson
Director, 10% owner
Feb 17, 2021Buy+1,285,714$3.50$4.50M8,053,298
Advisors Llc Orbimed
Director, 10% owner
Feb 17, 2021Buy+1,285,714$3.50$4.50M8,053,298
Richard A. Miller Md
President and CEO, Director
Feb 17, 2021Buy+100,000$3.50$350.00K1,278,515
Holdings A/S Novo
10% owner
Jul 8, 2020Sale−741,440$5.37$3.98M1,389,498
Holdings A/S Novo
10% owner
Jul 7, 2020Sale−796,622$5.25$4.18M2,130,938

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
30.39%
18M shares short
Days to cover
18.9
At 1M shares a day
Change since last report
-1.2%
From 18M shares
Short volume, 20 days
58.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Corvus Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 42,687 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?